Aclaris Therapeutics Inc (NASDAQ:ACRS) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 3,060,000 shares, a decrease of 16.6% from the January 15th total of 3,670,000 shares. Based on an average daily trading volume, of 822,800 shares, the short-interest ratio is presently 3.7 days. Currently, 9.2% of the shares of the stock are short sold.
A number of hedge funds have recently made changes to their positions in ACRS. MFN Partners Management LP lifted its stake in Aclaris Therapeutics by 166.7% in the 4th quarter. MFN Partners Management LP now owns 4,000,000 shares of the biotechnology company’s stock worth $7,560,000 after purchasing an additional 2,500,000 shares in the last quarter. Man Group plc lifted its stake in Aclaris Therapeutics by 81.5% in the 3rd quarter. Man Group plc now owns 3,734,793 shares of the biotechnology company’s stock worth $4,034,000 after purchasing an additional 1,676,857 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Aclaris Therapeutics by 41.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,782,297 shares of the biotechnology company’s stock worth $5,259,000 after purchasing an additional 813,581 shares in the last quarter. Broadfin Capital LLC lifted its stake in Aclaris Therapeutics by 16.5% in the 4th quarter. Broadfin Capital LLC now owns 1,888,039 shares of the biotechnology company’s stock worth $3,568,000 after purchasing an additional 268,039 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in Aclaris Therapeutics in the 4th quarter worth $425,000. Institutional investors and hedge funds own 74.26% of the company’s stock.
Several research analysts recently weighed in on the stock. Leerink Swann raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, October 22nd. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 8th. Svb Leerink reaffirmed an “outperform” rating on shares of Aclaris Therapeutics in a report on Thursday, January 2nd. Finally, ValuEngine raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $6.67.
Shares of ACRS stock opened at $1.35 on Friday. The stock has a market cap of $55.87 million, a P/E ratio of -0.30 and a beta of 1.06. Aclaris Therapeutics has a 52 week low of $0.74 and a 52 week high of $7.54. The company has a quick ratio of 3.73, a current ratio of 3.73 and a debt-to-equity ratio of 0.35. The company’s fifty day simple moving average is $1.66 and its two-hundred day simple moving average is $1.48.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
See Also: What is Green Investing?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.